Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD, a leader in innovative cancer detection technology, is set to participate in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Stacey Stevens, President and CEO, will present on March 17, 2022, at 8:00 a.m. EST. Interested parties can view the webcast at the provided link. iCAD is renowned for its advanced cancer detection and therapy solutions, aimed at improving patient outcomes. The company addresses various risks and uncertainties in its forward-looking statements, emphasizing a commitment to innovation in the healthcare sector.
iCAD, a leader in medical technology, announced its solutions are among the first to integrate with the NVIDIA AI Enterprise software suite. This partnership aims to enhance the deployment and scalability of its breast health technologies, including ProFound AI and PowerLook. The integration allows healthcare organizations to streamline AI workloads in virtualized data centers. iCAD's solutions improve cancer detection efficiency and risk assessment, promising faster adoption for hospitals, particularly amidst ongoing pandemic challenges.
iCAD, a leader in medical technology for cancer detection, announced its participation in the 42nd Annual Cowen Health Care Conference from March 7-9, 2022.
Stacey Stevens, President and CEO, will present on March 8, 2022, at 10:30 a.m. EST. Investors can access the live webcast here.
iCAD continues to focus on innovative solutions for cancer care, showcasing its commitment to improving patient outcomes through advanced technology.
iCAD, a leader in cancer detection and therapy solutions, reported Q4 2021 revenues of $7.8 million, down 25% from $10.5 million in Q4 2020. Annual revenues rose 13.3% to $33.6 million. The company faced challenges from the Omicron variant, which impacted order processing. A net loss of $4.1 million for Q4 was reported, compared to $1.6 million loss in the same quarter last year. The company maintains a cash reserve of $34.3 million. New initiatives include launching the ProFound AI Risk tool and securing a global distribution agreement with Arterys.
iCAD, a leader in medical technology focused on innovative cancer detection and therapy solutions, will release its financial results for Q4 and the full year ending December 31, 2021, on February 28, 2022, post-market closure. A conference call will follow at 4:30 PM ET, where they will discuss the results. Investors can join the call through domestic and international numbers provided or via a webcast link. For further information about iCAD, visit their official website.
NASHUA, N.H., Feb. 08, 2022 – iCAD, a leader in cancer detection and therapy solutions, will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. Stacey Stevens, President and incoming CEO of iCAD, will engage in a fireside chat on February 15 at 4:00 p.m. EST, hosted by analyst Marie Thibault. This event will not be webcast. For more details, contact your BTIG representative.
For further information about iCAD, visit www.icadmed.com.
iCAD has secured an Authorization to Operate (ATO) from the U.S. Department of Defense for its breast AI platform. This milestone allows the technology to be used in military healthcare facilities, a significant market opportunity. The ProFound AI platform enhances breast cancer detection by improving reader sensitivity by 8% and specificity by 7%, while reducing reading times by 52.7%. With over 500 military healthcare facilities and 9.62 million beneficiaries, this authorization underscores the platform's security and reliability in supporting cancer screening efforts.
iCAD appointed Dana Brown and Timothy Norris Irish as independent members of its Board of Directors, effective January 10, 2022. Dana Brown, with over 30 years in technology and women's breast health, previously held roles at Susan G. Komen and United Way. Timothy Norris Irish, a professor at King’s College London, brings experience from the healthcare sector. Stacey Stevens, iCAD's President and incoming CEO, also joined the board, increasing total members to eight. Their expertise aims to enhance iCAD’s innovative cancer detection and therapy solutions and drive shareholder value.
iCAD, Inc. (NASDAQ: ICAD) announced its preliminary estimated revenues for Q4 2021, expecting figures between $7.8 million and $8.0 million. For the entire year, revenues are projected to be approximately $33.6 million to $33.8 million. The company faced significant challenges due to the COVID-19 Omicron variant, which disrupted staffing and delayed sales. Despite these setbacks, iCAD remains confident in returning to a growth trajectory in 2022 by adapting its commercial operations to evolving market needs.
iCAD, a leader in medical technology, announced participation in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022. The company's President and incoming CEO, Stacey Stevens, will join a panel titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5 at 2:00 pm ET. This virtual event will highlight key topics in life sciences and feature discussions with industry experts and company management teams. For more details, interested parties can register for the event online.